Masuda Hiroki, Mori Masahiro, Uchida Tomohiko, Uzawa Akiyuki, Ohtani Ryohei, Kuwabara Satoshi
Department of Neurology, Graduate School of Medicine, Chiba University, Japan.
J Neuroimmunol. 2017 Apr 15;305:102-107. doi: 10.1016/j.jneuroim.2017.01.024. Epub 2017 Feb 4.
Soluble CD40 ligand (sCD40L) is reported to disrupt the blood-brain barrier (BBB). Cerebrospinal fluid (CSF) and serum sCD40L levels were measured in 29 multiple sclerosis (MS), 29 neuromyelitis optica spectrum disorder (NMOSD), and 27 disease control (DC) patients. In MS, serum sCD40L levels were higher than in DCs and positively correlated with the CSF/serum albumin ratio (Qalb). In NMOSD, CSF sCD40L levels were significantly increased compared to DCs, and were correlated to Qalb, CSF cell counts, protein concentrations, and interleukin-6 levels. sCD40L could be involved in BBB disruption in MS, whereas it may contribute to CNS inflammation in NMOSD.
据报道，可溶性CD40配体（sCD40L）会破坏血脑屏障（BBB）。对29例多发性硬化症（MS）患者、29例视神经脊髓炎谱系障碍（NMOSD）患者和27例疾病对照（DC）患者的脑脊液（CSF）和血清sCD40L水平进行了测量。在MS患者中，血清sCD40L水平高于疾病对照患者，且与脑脊液/血清白蛋白比率（Qalb）呈正相关。在NMOSD患者中，脑脊液sCD40L水平与疾病对照患者相比显著升高，且与Qalb、脑脊液细胞计数、蛋白质浓度和白细胞介素-6水平相关。sCD40L可能参与了MS患者血脑屏障的破坏，而在NMOSD中它可能导致中枢神经系统炎症。
